Gene

ARID1A

AT-rich interaction domain 1A

Explore in graph →CI-GENE-00011298HGNC:11110 ENSG00000117713 NCBI 8289 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (14)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–14 of 14 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ARID1A Loss5
(oncogenic)	Ovarian Clear Cell Adenocarcinoma	Oncogenic	B	Supports Oncogenicity	4	submitted	EID13135 Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt…

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Hepatocellular Carcinoma (MSK, JCO Precis Oncol 2023) hcc_jcopo_msk_2023	Hepatocellular Carcinoma	Ssm

Literature

Linked publications (6)

25 per page, newest first.

pubmedPublishedShowing 1–6 of 6 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma.
· Hum Pathol · 2015 · PMID 25628030 · validated civic_curation pubmed
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
· Mod Pathol · 2012 · PMID 22101352 · validated civic_curation pubmed
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
· Gynecol Oncol · 2023 · PMID 37418832 · validated civic_curation pubmed
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
· Nat Med · 2015 · PMID 25686104 · validated

ARID1A Loss + ARID1A Wildtype1
Dasatinib	Ovarian Clear Cell CarcinomaUNRESOLVED	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11789 In this phase 2 clinical study, 28 patients with recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum, or Endometrium, harboring either wild-type ARID1A or ARID1A loss were recruite… (full text at CIViC) PMID 37418832 · O'Cearbhaill et al., 2023 · Open in CIViC	civic

ARID1A Loss + ARID1A Wildtype1

Dasatinib

Ovarian Clear Cell CarcinomaUNRESOLVED

Predictive

Does Not Support Sensitivity Response

accepted

EID11789

In this phase 2 clinical study, 28 patients with recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum, or Endometrium, harboring either wild-type ARID1A or ARID1A loss were recruite… (full text at CIViC)

PMID 37418832 · O'Cearbhaill et al., 2023 · Open in CIViC

civic

ARID1A Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11907 This study sequenced 73 DLBCL tumors (34 with matched constitutional DNA) and reported 322 genes they deemed recurrently mutated. Only genes that have been confirmed by other similar studies were adde… (full text at CIViC) PMID 23292937 · Zhang et al., 2013 · Open in CIViC	civic

ARID1A Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11907

This study sequenced 73 DLBCL tumors (34 with matched constitutional DNA) and reported 322 genes they deemed recurrently mutated. Only genes that have been confirmed by other similar studies were adde… (full text at CIViC)

PMID 23292937 · Zhang et al., 2013 · Open in CIViC

civic

ARID1A Mutation + ARID1B MutationARID1A ARID1B1
(functional)	—UNRESOLVED	Functional	B	Supports Loss Of Function	3	submitted	EID12642 Concurrent inactivating mutations in ARID1A and ARID1B were identified in 12 of 24 BRG1/INI1-intact dedifferentiated endometrial or ovarian carcinomas, with all co-mutated tumours showing complete los… (full text at CIViC) PMID 27562491 · Coatham et al., 2016 · Open in CIViC	civic

ARID1A Mutation + ARID1B MutationARID1A ARID1B1

(functional)

—UNRESOLVED

Functional

Supports Loss Of Function

submitted

EID12642

Concurrent inactivating mutations in ARID1A and ARID1B were identified in 12 of 24 BRG1/INI1-intact dedifferentiated endometrial or ovarian carcinomas, with all co-mutated tumours showing complete los… (full text at CIViC)

PMID 27562491 · Coatham et al., 2016 · Open in CIViC

civic

ARID1A P1175FS*51
Dasatinib	Ovarian Clear Cell CarcinomaUNRESOLVED	Predictive	D	Supports Sensitivity Response	2	accepted	EID4826 In an in vitro study, a HCH1 cell line expressing ARID1A P1172fs mutation demonstrated increased sensitivity to dasatinib treatment, compared to ES2, KK and RMG-1 cells expressing wild-type ARID1A. Se… (full text at CIViC) PMID 27364904 · Miller et al., 2016 · Open in CIViC	civic

ARID1A P1175FS*51

Dasatinib

Ovarian Clear Cell CarcinomaUNRESOLVED

Predictive

Supports Sensitivity Response

accepted

EID4826

In an in vitro study, a HCH1 cell line expressing ARID1A P1172fs mutation demonstrated increased sensitivity to dasatinib treatment, compared to ES2, KK and RMG-1 cells expressing wild-type ARID1A. Se… (full text at CIViC)

PMID 27364904 · Miller et al., 2016 · Open in CIViC

civic

ARID1A Q185*1
(oncogenic)	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11813 Reported as significantly mutated in BL per the cited study. An arbitrarily selected variant from the study is included here. PMID 30617194 · Grande et al., 2019 · Open in CIViC	civic

ARID1A Q185*1

(oncogenic)

Burkitt Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11813

Reported as significantly mutated in BL per the cited study. An arbitrarily selected variant from the study is included here.

PMID 30617194 · Grande et al., 2019 · Open in CIViC

civic

ARID1A Q456*1
Dasatinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID4487 In an in vitro study, human colorectal cancer cell line HCT116 cell line was made to homozygously express ARID1A Q546* via adeno-associated virus-mediated somatic gene targeting. Compared to the paren… (full text at CIViC) PMID 27364904 · Miller et al., 2016 · Open in CIViC	civic

ARID1A Q456*1

Dasatinib

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID4487

In an in vitro study, human colorectal cancer cell line HCT116 cell line was made to homozygously express ARID1A Q546* via adeno-associated virus-mediated somatic gene targeting. Compared to the paren… (full text at CIViC)

PMID 27364904 · Miller et al., 2016 · Open in CIViC

civic

ARID1A Underexpression3
(prognostic)	Clear Cell Renal Cell Carcinoma	Prognostic	B	Supports Poor Outcome	3	accepted	EID5676 This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC) PMID 25628030 · Park et al., 2015 · Open in CIViC	civic
〃	Ovarian Clear Cell CarcinomaUNRESOLVED	Prognostic	B	Supports Poor Outcome	3	accepted	EID5787 In a study of 60 individuals with ovarian clear cell carcinoma, ARID1A expression was analyzed using immunohistochemistry. Of these 60 patients, 9 (15%) patients had a loss of ARID1A expression. Resul… (full text at CIViC) PMID 22101352 · Katagiri et al., 2012 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Prognostic	D	Supports Poor Outcome	4	accepted	EID5675 In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower… (full text at CIViC) PMID 22808142 · Wang et al., 2012 · Open in CIViC	civic

ARID1A Underexpression3

(prognostic)

Clear Cell Renal Cell Carcinoma

Prognostic

Supports Poor Outcome

accepted

EID5676

This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC)

PMID 25628030 · Park et al., 2015 · Open in CIViC

civic

〃

Ovarian Clear Cell CarcinomaUNRESOLVED

Prognostic

Supports Poor Outcome

accepted

EID5787

In a study of 60 individuals with ovarian clear cell carcinoma, ARID1A expression was analyzed using immunohistochemistry. Of these 60 patients, 9 (15%) patients had a loss of ARID1A expression. Resul… (full text at CIViC)

PMID 22101352 · Katagiri et al., 2012 · Open in CIViC

civic

〃

Malignant Gastric Neoplasm

Prognostic

Supports Poor Outcome

accepted

EID5675

In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower… (full text at CIViC)

PMID 22808142 · Wang et al., 2012 · Open in CIViC

civic